Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 6, Issue 224, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3007947
Keywords
-
Categories
Funding
- European Community [259015]
- Associazione Italiana per la Ricerca sul Cancro (AIRC) IG [12812]
- AIRC MFAG [11349]
- Farmacogenomica-5 per mille MIUR-Fondazione Piemontese per la Ricerca sul Cancro-ONLUS
- AIRC Special Program Molecular Clinical Oncology 5 per mille [9970]
- FPRC 5 per mille Ministero della Salute
- Ministero dell'Istruzione, dell'Universite e della Ricerca, progetto PRIN
- Progetti di Ateneo, Universita di Torino [codice ORTO11RKTW]
- Oncologia Ca Granda ONLUS (OCGO) Fondazione
- Grant Terapia Molecolare dei Tumori from OCGO Fondazione
Ask authors/readers for more resources
Colorectal cancers (CRCs) that are sensitive to the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop resistance within several months of initiating therapy. We report the emergence of polyclonal KRAS, NRAS, and BRAF mutations in CRC cells with acquired resistance to EGFR blockade. Regardless of the genetic alterations, resistant cells consistently displayed mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) activation, which persisted after EGFR blockade. Inhibition of MEK1/2 alone failed to impair the growth of resistant cells in vitro and in vivo. An RNA interference screen demonstrated that suppression of EGFR, together with silencing of MEK1/2, was required to hamper the proliferation of resistant cells. Indeed, concomitant pharmacological blockade of MEK and EGFR induced prolonged ERK inhibition and severely impaired the growth of resistant tumor cells. Heterogeneous and concomitant mutations in KRAS and NRAS were also detected in plasma samples from patients who developed resistance to anti-EGFR antibodies. A mouse xenotransplant from a CRC patient who responded and subsequently relapsed upon EGFR therapy showed exquisite sensitivity to combinatorial treatment with MEK and EGFR inhibitors. Collectively, these results identify genetically distinct mechanisms that mediate secondary resistance to anti-EGFR therapies, all of which reactivate ERK signaling. These observations provide a rational strategy to overcome the multifaceted clonal heterogeneity that emerges when tumors are treated with targeted agents. We propose that MEK inhibitors, in combination with cetuximab or panitumumab, should be tested in CRC patients who become refractory to anti-EGFR therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available